5th U.S. Circuit Court Temporarily Restores In-Person Mifepristone Requirement, Blocking Telehealth And Mail

A federal appeals court on Friday temporarily reinstated a nationwide requirement that abortion pills be obtained in person, sharply curbing access to mifepristone through telehealth and mail.

“A federal appeals court has restricted access to one of the most common means of abortion in the U”

ABC7 New York

The ruling came from the 5th US Circuit Court of Appeals, which granted the state of Louisiana’s request to reinstate a requirement that abortion pills be dispensed in person.

ABC7 New York

CNN described the decision as a “major victory in the anti-abortion movement’s war against medication abortion,” noting that the opinion was written by Trump-appointed Circuit Judge Kyle Duncan and joined by Circuit Judges Leslie Southwick and Kurt Engelhardt.

NBC News reported that the court’s action blocks people’s ability to obtain mifepristone “through telehealth and by mail,” and that the ruling represents a victory for opponents of abortion rights.

The BBC said the Fifth Circuit “temporarily reinstated a requirement that abortion pills be obtained in person,” rather than allow them to be obtained by post or at a pharmacy through telemedicine.

Multiple outlets quoted the appeals court’s reasoning that “Every abortion facilitated by FDA's action cancels Louisiana's ban on medical abortions and undermines its policy that 'every unborn child is human being from the moment of conception and is, therefore, a legal person,'” which the court said in its order.

The decision also set up immediate legal uncertainty for drug distribution, with NBC News reporting that Danco Laboratories filed for “a one-week stay — or pause — on the court’s order” and argued that “It is now unclear whether pharmacies nationwide may still dispense mifepristone to women tonight.”

The appeals court ruling sits atop a yearslong legal battle over medication abortion access after the US Supreme Court overturned Roe v. Wade and after the FDA changed how mifepristone could be dispensed.

CNN said the ruling stems from a lawsuit filed by Louisiana last year against the US Food and Drug Administration after President Donald Trump’s administration refused to act on calls to reinstate the in-person dispensing requirement for abortion pills through the regulatory process.

ACI Prensa

CNN also traced the regulatory shift: since the Covid-19 pandemic, abortion-seekers have been able to obtain mifepristone through telehealth appointments, and President Joe Biden’s administration finalized rules that ended the requirement that the pills be obtained through an in-person doctor’s visit in 2023.

NBC News described the pandemic-era change as temporary under the FDA “under President Joe Biden” and said it became permanent in 2023, while Louisiana challenged that FDA regulation in federal court last year.

The BBC added that the decision pauses a 2023 regulation from the FDA that allowed doctors to send pills without seeing patients in person, and said the move is meant to curb access “in states where abortion is banned.”

ABC7 New York said the FDA permanently lifted the in-person requirement in 2023, and that “Since the Supreme Court's 2022 ruling that overturned Roe v. Wade and allowed enforcement of abortion bans, prescriptions by mail have become a major way that abortions are provided.”

NBC News said the district court judge granted the FDA’s request to pause Louisiana’s lawsuit until the Trump administration finished conducting its own safety review, but also denied Louisiana’s request to reinstate in-person dispensing while the case played out.

The ruling triggered immediate, sharply divided reactions from government officials, advocacy groups, and the companies that make mifepristone.

Louisiana Attorney General Liz Murrill celebrated the decision, with CNN reporting that she wrote on X, “I look forward to continuing to defend women and babies as this case continues,” and NBC News quoting her as saying “I look forward to continuing to defend women and babies as this case continues.”

Anti-abortion groups also framed the decision as a corrective to what they called deregulation, with Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, telling CNN that “Women and children suffer and state sovereignty is violated every day the FDA allows abortion drugs to flood the mail.”

On the other side, ACLU attorney Julia Kaye said the decision “defies clear science and settled law and advances an anti-abortion agenda that is deeply unpopular with the American people,” according to the BBC, while NBC News quoted Kaye saying, “Anti-abortion politicians have just made it much harder for people everywhere in the country to get a medication that abortion and miscarriage patients have been safely using for more than 25 years.”

Planned Parenthood Action Fund CEO Alexis McGill Johnson said in a statement that its health centers “remain committed to providing abortion care where legal,” and ABC7 New York quoted ACLU lawyer Julia Kaye saying, “This is going to affect patients' access to abortion and miscarriage care in every state in the nation.”

The drugmakers also responded, with CNN quoting GenBioPro CEO Evan Masingill saying the company was “alarmed by this court’s decision to ignore the FDA’s rigorous science and decades of safe use of mifepristone in a case pursued by extremist abortion opponents.”

Politico said the case was set up for a Supreme Court showdown and quoted Molly Meegan of the American College of Obstetricians and Gynecologists saying, “I expect briefs to be filed likely next week.”

While all the outlets described the same core legal action—Friday’s Fifth Circuit order temporarily reinstating in-person dispensing—coverage diverged in emphasis, especially around the court’s rationale, the role of FDA review, and the practical consequences.

CNN framed the decision as a “major victory” for anti-abortion opponents and highlighted the court’s view that federal regulations create “an effective way for an out-of-state prescriber to place the drug in the hands of Louisianans in defiance of Louisiana law.”

Associated Press

NBC News focused on the immediate operational disruption, quoting Danco Laboratories’ motion that “Never before has a federal court purported to immediately change a drug’s conditions of use upon issuance of its order,” and warning that “It is now unclear whether pharmacies nationwide may still dispense mifepristone to women tonight.”

Politico described the ruling as “the biggest rollback in access to abortion since the Supreme Court’s 2022 ruling overturning Roe v. Wade,” and said the court rejected arguments that the state lacked standing and that the court should “hit pause” while the FDA conducted its own review.

The Hill and ABC7 New York both quoted the appeals court’s language about Louisiana’s ban and “every unborn child,” but The Hill also included a direct critique from Brittany Fonteno of The National Abortion Federation saying, “Make no mistake: this ruling is not grounded in science or patient safety.”

ABC7 New York added a technical timeline, saying FDA officials under President Joe Biden stated that after “more than 20 years of monitoring mifepristone use” and reviewing “dozens of studies involving thousands of women,” it was clear women could safely use the pill without direct supervision.

Fox News emphasized the court’s own acknowledgement of nationwide effect, quoting that the order would have “as a practical matter, have a nationwide effect,” and it also highlighted the court’s criticism that the FDA “could not say when that review might be complete and admitted it was still collecting data.”

The ruling’s consequences extend beyond the courtroom, with multiple outlets describing how the temporary block could force patients to travel and how it could set up a Supreme Court fight.

“US court limits mail-order access to abortion pill mifepristone A US court has issued an order significantly restricting access to the abortion pill mifepristone by mail”

BBC

Stateline said the block will remain in effect as the lower court case proceeds, and that “the FDA could file an emergency appeal to the U.S. Supreme Court in the coming weeks.”

BBC

It also reported that without access to telemedicine and the opportunity to receive the medication through the mail, people in “13 states with near-total abortion bans may have to travel to another state to get an abortion.”

Stateline quoted Regina Davis-Moss, CEO of In Our Own Voice: National Black Women’s Reproductive Justice Agenda, saying, “Reinstating in-person dispensing requirements would force people to travel farther, take more time off work, and absorb costs that are simply too high.”

NBC News said Danco Laboratories filed for a one-week stay and would go to the U.S. Supreme Court if the appellate court does not grant relief, while Politico said the temporary ruling “tee[s] up SCOTUS showdown.”

The Hill said the ruling sets up a likely appeal to the Supreme Court and overrides a lower court’s ruling earlier this month that had paused the lawsuit while the Trump administration’s FDA conducts a review on the safety of mifepristone.

Fox News framed the next phase as a likely Supreme Court battle, saying the ruling sets up “a likely Supreme Court battle over abortion access.”